Literature DB >> 18470514

Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective.

Paolo Zanotti-Fregonara, Domenico Rubello, Elif Hindié.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18470514     DOI： 10.1007/s00259-008-0823-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  20 in total

1.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

Authors:  P W Ladenson; L E Braverman; E L Mazzaferri; F Brucker-Davis; D S Cooper; J R Garber; F E Wondisford; T F Davies; L J DeGroot; G H Daniels; D S Ross; B D Weintraub
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

2.  Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.

Authors:  Markus Luster; Ralph Felbinger; Markus Dietlein; Christoph Reiners
Journal:  Thyroid       Date:  2005-10       Impact factor: 6.568

3.  Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.

Authors:  Christian Pötzi; Abbas Moameni; Georgios Karanikas; Josef Preitfellner; Alexander Becherer; Christian Pirich; Robert Dudczak
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

Review 4.  rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

Authors:  Markus Luster; Francesco Lippi; Barbara Jarzab; Petros Perros; Michael Lassmann; Christoph Reiners; Furio Pacini
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

5.  A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.

Authors:  Richard T Kloos; Ernest L Mazzaferri
Journal:  J Clin Endocrinol Metab       Date:  2005-06-21       Impact factor: 5.958

Review 6.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.

Authors:  Martin Schlumberger; Gertrud Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Furio Pacini; Christoph Reiners; Franco Sánchez Franco; Anthony Toft; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

7.  Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin.

Authors:  A A Driedger; N Kotowycz
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

8.  Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.

Authors:  C F A Eustatia-Rutten; J W A Smit; J A Romijn; E P M van der Kleij-Corssmit; A M Pereira; M P Stokkel; J Kievit
Journal:  Clin Endocrinol (Oxf)       Date:  2004-07       Impact factor: 3.478

9.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Authors:  Tania Pilli; Ernesto Brianzoni; Francesca Capoccetti; Maria Grazia Castagna; Sara Fattori; Angela Poggiu; Gloria Rossi; Francesca Ferretti; Elisa Guarino; Luca Burroni; Angelo Vattimo; Claudia Cipri; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958

10.  Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study.

Authors:  Hanna O Mäenpää; Jorma Heikkonen; Leila Vaalavirta; Mikko Tenhunen; Heikki Joensuu
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240
View more
  2 in total

1.  Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective.

Authors:  Markus Luster; Martin Schlumberger; Furio Pacini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-18       Impact factor: 9.236

Review 2.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.